ABAstri Budikayanti

Astri Budikayanti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Astri Budikayanti has a total of 80 co-authors. Here are the top co-authors by number of shared publications:

  • Fitri Octaviana

    Department of Neurology (AB, IR, LA, DNL, FO) and Community Medicine Department (HH, JP), Faculty of Medicine Universitas Indonesia/Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia

    5 shared publications
  • Fitri Octaviana

    Neurology Jakarta Special Capital Region of Jakarta 10430 Universitas Indonesia Fakultas Kedokteran

    5 shared publications
  • Manfaluthy Hakim

    Neurology Department, Faculty of Medicine, Universitas Indonesia/Dr, Cipto Mangunkusumo National Referral Hospital, Jakarta, Indonesia

    4 shared publications
  • Luh Ari Indrawati

    Department of Neurology, Faculty of Medicine, Universitas Indonesia/ Cipto Mangunkusumo General Hospital, Jakarta, Indonesia

    3 shared publications
  • Adrian Ridski Harsono

    Neurology Department, Faculty of Medicine, Universitas Indonesia/Dr, Cipto Mangunkusumo National Referral Hospital, Jakarta, Indonesia

    2 shared publications
  • Ahmad Yanuar Safri

    Neurology Department, Faculty of Medicine, Universitas Indonesia/Dr, Cipto Mangunkusumo National Referral Hospital, Jakarta, Indonesia

    2 shared publications

Latest Publications

  • Open Access

    Effect of vitamin D supplementation on metabolic syndrome and atherosclerosis biomarkers in epilepsy: a randomized controlled trial

    by Sri Handayani, Zen Hafy, Fitri Octaviana, Zulkhair Ali, Nita Parisa, Astri Budikayanti, Dessy Agustini, Radiyati Umi Partan

    Aim To analyze the effect of vitamin D administration on serum 25(OH)D levels and biomarkers of metabolic syndrome and atherosclerosis (homeostatic model assessment of insulin resistance [HOMA-IR], adiponectin, homocysteine, and high sensitivity C-reactive protein [hs-CRP]) in epilepsy patients receiving enzymatic antiseizure medications (ASMs). Methods This double-blind, randomized, placebo-controlled trial randomized 40 adult epilepsy patients treated with enzymatic ASMs to receive vitamin D3 (2,000 IU/day) or placebo for 12 weeks. The primary outcome was the change in serum 25-hydroxyvitamin D (25[OH]D) levels. Secondary outcomes included changes in HOMA-IR, adiponectin, homocysteine, and hs-CRP. Data were analyzed using a per-protocol approach. Results Thirty-four patients completed the study. Vitamin D supplementation yielded a significantly greater increase in serum 25(OH)D (10.67 ± 8.16 vs. –1.29 ± 3.96 ng/mL; p < 0.001) and adiponectin (1.38 ± 3.05 vs. 0.34 ± 1.89 µg/mL; p = 0.045), as well as a significantly greater reduction in hs-CRP (–6.74 ± 14.65 vs. 1.81 ± 7.75 mg/L; p = 0.041) compared with placebo. Conversely, no significant differences were observed between groups regarding the changes in HOMA-IR (–0.24 ± 3.71 vs. –0.14 ± 3.38; p = 0.940) or homocysteine (7.90 ± 1.79 vs. 8.15 ± 2.70 µmol/L; p = 0.290). Conclusion Vitamin D supplementation (2,000 IU/day) effectively restores 25(OH)D levels and improves adiponectin and hs-CRP in epilepsy patients on enzymatic ASMs, suggesting a potential benefit for cardiovascular risk reduction. However, vitamin D alone did not prevent the rise in homocysteine, likely due to the concurrent cessation of B-vitamin supplementation.


  • Open Access

    Medication adherence in epilepsy: the role of adverse drug reactions and patient knowledge-attitude-behavior

    by Ana Hulliyyatul Jannah, Nadia Devianca, Retnosari Andrajati, Fitri Octaviana, Winnugroho Wiratman, Luh Ari Indrawati, Adrian Ridski Harsono, Manfaluthy Hakim, Ahmad Yanuar Safri, Nurul Fadli, et al.

    Background: Adherence to epilepsy treatment varies greatly and is often compromised by adverse drug reactions. Spontaneous reporting of these reactions has improved pharmacovigilance in many countries. Knowledge, attitudes, and behavior are also key factors influencing treatment adherence. This study aimed to investigate the types of adverse drug reactions in epilepsy, as well as the knowledge, attitudes, and behavior of patients, and how these factors relate to medication adherence. Methods: This cross-sectional study assessed adverse drug reactions using the Indonesian version of the Liverpool Adverse Event Profile and medication adherence with the Morisky Adherence Questionnaire. Knowledge, attitude and behavior were measured using a self-reported Indonesian knowledge-attitude-behavior questionnaire. Data were collected at two periods of time (2019 and 2022), in which the first period measured adherence, and adverse drug reactions, while the second period measured adherence, and adverse drug reactions, alongside knowledge, attitude, and behavior. Data were gathered from epilepsy patients at the neurology outpatient clinic at Cipto Mangunkusumo National Referral Hospital, and analyzed using Chi-square, likelihood ratio, independent t -test, or Mann–Whitney U Tests, followed by multivariate logistic regression. Results: Adherence rates in both periods exceeded 50% (50.88% vs. 55.70%). Adverse drug reactions were reported by 78.07% of subjects, and were significantly associated with non-adherence ( P = 0.007). The mean knowledge score was 15.41 ± 3.83, and lower knowledge scores were linked to higher odds of non-adherence. Although not statistically significant ( P = 0.077), higher knowledge scores showed a trend toward more frequent reporting of adverse drug reactions. Female subjects had higher odds of adherence compared to males ( P = 0.013). Conclusions: Our findings suggest that adverse drug reaction reporting, along with patient knowledge, attitudes, and behavior, are important factors associated with medication adherence. Targeted interventions by healthcare providers to support these areas may help improve adherence in people with epilepsy.


  • Decoding Speech Imagery: A Spectro-Spatial Approach to Electroencephalography Band Power Analysis

    by Nilam Fitriah, Hasballah Zakaria, Astri Budikayanti, Andriyan Bayu Suksmono, Tati Latifah Erawati Rajab Mengko

    Decoding speech imagery from brain signals potentially assists individuals with speech impairments. However, limited data and complex brain activity in recent studies have made accurate decoding challenging. We analyzed both the spectral (frequency) and spatial (location) aspects of brain activity to enhance decoding accuracy in small datasets. To our knowledge, previous studies have mainly used generated features without adequately considering spectro-spatial aspects. We trained machine learning with time-frequency representation (TFR) features using a public dataset from the Brain-Computer Interface (BCI) competition (BCI-DB) and our own recordings (PrimAudio-DB). The results showed prominent feature patterns of speech imagery in the frontal region and Gamma band, achieving accuracies of 98.6% in BCI-DB (exceeding benchmarks) and 81.7% in PrimAudio-DB. Moreover, our analysis revealed insights regarding speech differences (language and semantics). This study contributed to non-invasive speech imagery decoding and offered valuable insights for future speech rehabilitation and assistive technologies.


  • Open Access

    Development of a prosthetic arm with gesture recognition for enhanced social interaction

    by Thangavel Bhuvaneswari, Min Thu Soe, Yeo Bc, Lim Ws, Wildan Latief, Rio Wikanjaya, Anissa Feby Canintika, Witantra Dhamar Hutami, Ali Saleh Alhuraebi, Manfaluthy Hakim, et al.

    This paper presents the design and development of an affordable prosthetic arm capable of performing finger movements, such as opening and closing, in various patterns. The prosthetic arm utilizes an Arduino microcontroller and servo motors, aiming to create a user-friendly assistive device for individuals with upper limb disabilities through a Brain-Computer Interface (BCI). The device is intended for individuals with below-elbow (transradial) amputations, which may result from causes like trauma, cancer, or vascular diseases. Constructed with PLA+ materials, the prosthetic is designed for both comfort and durability, with 3D printing enabling cost-effective and customizable production. The prototype is tested for three movement patterns: default option 1: opening and closing all fingers starting from the pinky, option 2: opening and closing all fingers simultaneously, and option 3: opening and closing all fingers starting from the thumb. Test results are analyzed to evaluate the functionality and performance of the device. This innovative approach demonstrates the potential of a low-cost, highly functional prosthetic arm that can enhance mobility and independence for users, demonstrating the power of accessible, affordable technology for assistive applications.


  • Open Access

    The Effectiveness of Plasmapheresis Compared to Intravenous Immunoglobulin in Guillain-Barre Syndrome Patients

    by Alyssa Putri Mustika, Manfaluthy Hakim, Waode Satriana Sari, Fitri Octaviana, Astri Budikayanti, Ahmad Yanuar Safri, Winnugroho Wiratman, Luh Ari Indrawati, Nurul Fadli, Adrian Ridski Harsono, et al.

    Introduction : Guillain-Barré syndrome (GBS) is the second most common cause of acute and subacute general paralysis. The management is symptom-adjusting, but plasmapheresis (plasma exchange/PE) and intravenous immunoglobulin immunotherapy (IVIG) can be administered to accelerate the return of neurological function. This study aim to determine PE's effectiveness compared to IVIG in GBS patients and the side effects or complications that may arise. Method : The literature study is carried out on four databases. Selection is carried out using inclusion and exclusion criteria. The articles were screened and extracted independently by two investigators. Results : The literature study obtained three systematic review studies. In the first study, shows the outcomes in the form of improved Hughes Score (OR 1.9; 95% CI 1.11-3.28) and mortality (OR 0.8; 95% CI 0.31-2.29) against IVIG. The second study, outcomes shown in the form of improved disability scores (WMD -0.02, p: 0.83), and secondary outcomes such as mortality or relapse (p >0.05, respectively). The third study showed that IVIG had higher efficacy (OR 1.6, p: 0.067, 95% CI 0.972-2.587), shorter duration of hospitalization, 38 days, compared to 49-day PE therapy (SMD -3.389, 95% CI -11.601-4.824; p: 0.419), however, had higher side effect (OR 0.8, p: 0.430, 95% CI 0.389-1.495). Conclusion : PE efficacy is generally lower than IVIG, as indicated by disability scores/motor ability scores in various studies, as well as the duration of hospitalization. The safety of therapy is assessed by the side effects that appear and appear-more-often in IVIG therapy rather than PE.


  • Open Access

    The Impact of Post-COVID-19 Conditions on Sleep and Quality of Life in Indonesia: A Nationwide Cross-Sectional Study

    by Astri Budikayanti, Manfaluthy Hakim, Faradillah Mutiani, Sri Handayani, Nushrotul Lailiyya, Herlyani Khosama, Seilly Yunita Jehosua, Vivien Puspitasari, Pricilla Yani Gunawan, Yetty Hambarsari, et al.

    Background: Sleep disturbances are included in the six most commonly cited complaints in post-COVID-19 conditions. In order to find the optimal management approach and enhance Quality of Life (QoL), we intend to explore sleep disturbances that occur in post-COVID-19 conditions. Methods: This was a cross-sectional study conducted with interviews and questionnaires using the Pittsburgh Sleep Quality Index (PSQI) for assessing sleep quality, Insomnia Severity Index (ISI) for assessing insomnia, Epworth Sleepiness Scale (ESS) for assessing Excessive Daytime Sleepiness (EDS), STOP-BANG questionnaire for assessing Obstructive Sleep Apnea (OSA), and Short Form 36 (SF-36) for assessing QoL. We recruited respondents from several cities in Indonesia and performed an analysis to find the relationship between sleep disturbance and its association with QoL. Results: This study involved 757 respondents. They were predominantly female, with a median age of 39 years, no comorbidities, and had exhibited mild COVID-19 severity. Subjects with post-COVID-19 conditions experienced insomnia, poor sleep quality, normal sleepiness, and low risk of OSA. Sleep quality caused role limitations due to decreased physical and mental health. Insomnia caused role limitations due to emotional and social functioning problems. Meanwhile, OSA only affected physical functioning. Conclusion: Numerous aspects of patients’ QoL are affected by sleep disturbance in post-COVID-19 conditions. A comprehensive approach and coordinated care pathways must be effectively managed to improve QoL among individuals experiencing sleep disturbance.


  • Screening of Major Depression Disorder in Patients With Epilepsy in Indonesian National Referral Hospital

    by Astri Budikayanti, Izati Rahmi, Lilir Amalini, Diatri Nari Lastri, Herqutanto, Joedo Prihartono, Fitri Octaviana

    Major depressive disorder (MDD) is a common psychiatric disorder in patients with epilepsy (PWE). The Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) is one of the MDD screening tools used in PWE. This study aims to determine the accuracy of the valid and reliable NDDI-E Indonesian version as an MDD screening tool in PWE and investigate the prevalence and risk factors for the development of MDD in PWE. A diagnostic cross-sectional study was conducted at Cipto Mangunkusumo National Referral Hospital, Indonesia. Patients were PWE aged 18 years or older who visited the epilepsy outpatient clinic. The valid and reliable NDDI-E Indonesian version and Mini International Neuropsychiatric Interview (MINI) International Classification of Disease, 10th Revision (ICD-10) were used to diagnose MDD. In phase II of the study, diagnostic accuracy was evaluated using the receiver operative characteristic (ROC) curve method to obtain the area under the curve (AUC) and diagnostic 2 x 2 table to determine the cutoff point, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). During phase III of the study, eligible individuals were screened for MDD using the NDDI-E Indonesian version. Demographic and clinical data were collected. Data analysis was performed using the χ2 test, Mann-Whitney test, and multivariate logistic regression analysis. A total of 105 individuals were involved, and only 23 of them were found to experience MDD based on MINI ICD-10. The best cutoff point for the NDDI-E Indonesian version was ≥11, with a sensitivity of 91.3%, specificity 89%, PPV 70%, and NPV 97.3%. The AUC obtained from ROC analysis was 97.5% (95% CI 95-99%, p < 0.001). Then, the survey was completed by 79 individuals, predominantly male, mostly within the age range of 26-45 years. The prevalence of MDD in PWE was 50.6%, and the significant risk factors were seizure frequency ≥8 times a year and the presence of chronic diseases (p < 0.001). The NDDI-E Indonesian version was a screening tool with a high diagnostic accuracy to detect MDD in PWE at a cutoff point of 11. Poor seizure control and the presence of other chronic diseases were the risk factors correlated with MDD development in PWE.


  • Open Access

    Multidrug Resistance-1 C3435T Polymorphism and Carbamazepine Plasma Level in Indonesian Temporal Lobe Epilepsy Patients

    by Rianto Setiabudy, Astri Budikayanti, Herlyani Khosama, Fitri Octaviana, Donny Hamdani Hamid, Melva Louisa, Teguh A.S. Ranakusuma

    Background: Temporal lobe epilepsy (TLE) has the highest probability of becoming resistant. One of the causes was Polymorphism in multidrug resistant-1 (MDR1) C3435T. In Dr. Cipto Mangunkusumo Hospital, potential drug-resistant epilepsy prevalence was 84.51%; 66.6% of them used carbamazepine (CBZ) as antiseizure medication. This comparative cross-sectional study aimed to investigate MDR1 C3435T polymorphism and CBZ plasma level (plCBZ) in Indonesian TLE patients. Methods: TLE patient was selected consecutively; divided into drug-responsive (DRV) and drugresistant (DRE) groups. Healthy subjects were included as a control for the gene polymorphism comparison. MDR1 was identified using the restriction fragment length polymorphism PCR technique; C allele at 159 and 57bp while T allele at 216bp. High-performance liquid chromatography was used to determine plCBZ. Results: There were 86 subjects; 61 in the study group and 25 controls. The genotype distribution between them was 0.58 vs 0.42, x2=0.54, p=0.000. In the study group, CBZ within therapeutic doses (dCBZ) had outreached the therapeutic plCBZ and found similar in all genotypes. DRE criteria were found in 37 subjects. Distribution of C and T in DRV was 0.63 vs 0.37, x2=10.4; and DRE 0.55 vs 0.45 x2=6.17 (p=0.019). In Tukey’s multiple comparison post hoc test, CT in DRV had significantly lower dCBZ (330,36 ± 174,91 mg) and plCBZ (7.15 ± 2.64 mcg/mL) compared to all genotypes in DRE. Whereas mean dCBZ was around 800mg and plCBZ outreached the toxic level; TT was the highest. Conclusion: The genotype MDR1 distribution was similar in the normal population and DRE. Therapeutic plCBZ was achieved using the low dose. CT genotype responds to lower dCBZ, while TT genotype outreached the highest toxic plCBZ.


  • Top Cited Papers
    Open Access

    Sleep disturbance in post COVID-19 conditions: Prevalence and quality of life

    by Rimawati Tedjasukmana, Astri Budikayanti, Wardah Rahmatul Islamiyah, Anastasia Melissa Ayu Larasati Witjaksono, Manfaluthy Hakim

    Post COVID-19 conditions are complaints and symptoms in patients with a history of probable or confirmed COVID-19 after 3 months of the onset of COVID-19 and last at least 2 months. About 10–20% of people may experience post COVID-19 conditions, one of which is sleep disturbance. There is a wide range of prevalence of sleep disturbances from 6% to more than 70%. An online survey of the post COVID-19 conditions in various countries showed that 78.58% of subjects had sleep disturbances, including insomnia, sleep-disordered breathing, central disorders of hypersomnolence, circadian rhythm sleep-wake disorders, parasomnias, and sleep-related movement disorders. Sleep disturbance can be found starting from 2 weeks until 48 weeks or more after discharge or after having a negative COVID-19 test results. Women aged < 50 years old with severe COVID-19 infection reported a worse outcome. Several mechanisms may cause sleep disturbance in post COVID-19 condition, namely persistent viral infection and inflammation, immunity dysregulation, and mitochondrial dysfunction. Several studies discovered sleep disturbance was a major problem that affected different domains of QoL in post COVID-19 conditions. Significant correlation was found between several dimensions of SF-36 with moderate-to-severe insomnia in post COVID-19 conditions. Therefore, sleep disturbance is a major problem in post COVID-19 conditions and may affect patients' QoL, and the existence of sleep disturbance should be a concern in post COVID-19 conditions period. Further research is required to determine the prevalence based on agreed definition as well as methods to assess this condition and its impact on QoL.


  • Open Access

    The stigma paradox: Perception of quality-of-life in people with epilepsy among themselves, the family, and the general population in Indonesian urban areas

    by Astri Budikayanti, Aska Primardi, Luh Ari Indrawati, Donny Hamid, Julintari Indriyani, Izati Rahmi, Andre, Agus Supriyatna, Ismi Adhanisa Hamdani, Dina Listyaningrum, et al.